Letter : ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19
| Errataetall: |
CommentOn: Aliment Pharmacol Ther. 2020 Jul;52(2):276-283. - PMID 32359205 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 52(2020), 8 vom: 01. Okt., Seite 1422-1423 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prentice, Ralley E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 29.10.2020 Date Revised 10.01.2021 published: Print CommentOn: Aliment Pharmacol Ther. 2020 Jul;52(2):276-283. - PMID 32359205 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.16063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316747319 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316747319 | ||
| 003 | DE-627 | ||
| 005 | 20231225161741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.16063 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316747319 | ||
| 035 | |a (NLM)33105980 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prentice, Ralley E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Letter |b ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Aliment Pharmacol Ther. 2020 Jul;52(2):276-283. - PMID 32359205 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
| 650 | 7 | |a EC 3.4.15.1 |2 NLM | |
| 700 | 1 | |a Tjandra, Doug |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Mayur |e verfasserin |4 aut | |
| 700 | 1 | |a Lubel, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Fourlanos, Spiros |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Doug |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ani, Aysha |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 52(2020), 8 vom: 01. Okt., Seite 1422-1423 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2020 |g number:8 |g day:01 |g month:10 |g pages:1422-1423 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.16063 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2020 |e 8 |b 01 |c 10 |h 1422-1423 | ||